Advancing Cystic Fibrosis Management: The Evolving Role of Specialty and Managed Care Pharmacists

This activity was originally presented live at Asembia's AXS25 Summit in Las Vegas, Nevada on April 28, 2025.

Program Description
Cystic fibrosis (CF) is a genetic disorder that causes thick, sticky mucus to build up in the lungs, pancreas, and other organs, leading to chronic respiratory infections and impaired digestion. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators improve CFTR protein function, while airway clearance therapies, inhaled mucolytics, and pancreatic enzyme replacement help manage symptoms and enhance quality of life. However, many patients face barriers to accessing CFTR modulators, struggle with adherence to complex medication regimens, or require alternative options due to rare mutations or drug resistance. This activity will provide insights into CF disease burden, advancements in CFTR modulators and emerging therapies, and patient-centered strategies to improve treatment access and adherence. Specialty and managed care pharmacists will navigate considerations for treatment selection to enhance clinical outcomes and quality of life for individuals with CF. Included will be patient cases and faculty perspectives on the role of pharmacists in CF care, covering aspects such as patient education, individualized therapy selection, and approaches to resolving treatment and management challenges.

Target Audience: Managed care and specialty pharmacists

Type of Activity: Application
Release date: May 6, 2025
Expiration date: May 6, 2026
Learner level: Intermediate
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify the burden of disease associated with cystic fibrosis (CF)
• Analyze the safety and efficacy of current and emerging therapies for CF
• Adapt current therapies into CF management based on patient-specific characteristics
• Investigate patient-centered strategies that improve patient access to CF treatment

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-123-H01-P. The activity is available for CE credit through May 6, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Julie Galipean, PharmD, BCPS, has the following relevant financial relationships with commercial interests to disclose:

Consultant: US Cystic Fibrosis Health Care Provider Advisory Panel

David C. Young, PharmD, has the following relevant financial relationships with commercial interests to disclose:

Grant/Research Support: Cystic Fibrosis Foundation
Consultant: Wolters Kluwer

The following contributors have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Liza Patel, RPh, PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta, and Rebecca Green.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms